PROGRESSION-FREE SURVIVAL AS A SURROGATE ENDPOINT FOR OVERALL SURVIVAL IN PATIENTS WITH RELAPSED OR REFRACTORY MULTIPLE MYELOMA

被引：5
|
作者：
Dimopoulos, M. [1 ]
Sonneveld, P. [2 ]
Nahi, H. [3 ]
Kumar, S. [4 ]
Hashim, M. [5 ]
Kulakova, M. [5 ]
Duran, M. [5 ]
Heeg, B. [5 ]
Lam, A. [6 ]
Dearden, L. [6 ]
机构：
[1] Univ Athens, Athens, Greece
[2] Erasmus MC, Rotterdam, Netherlands
[3] Karolinska Inst, Stockholm, Sweden
[4] Mayo Clin, Rochester, MN USA
[5] Ingress Hlth, Rotterdam, Netherlands
[6] Janssen Global Serv LLC, Raritan, NJ USA
来源：
VALUE IN HEALTH | 2017年 / 20卷 / 09期
关键词：
D O I：
10.1016/j.jval.2017.08.064
中图分类号：
F [经济];
学科分类号：
02 ;
摘要：
CN5
引用
收藏
页码：A408 / A408
页数：1
相关论文
共 50 条
  • [21] PROGNOSTICATION OF RESPONSE TO BORTEZOMIB, PROGRESSION FREE AND OVERALL SURVIVAL IN RELAPSED/REFRACTORY MYELOMA PATIENTS
    Kyrtsonis, M. C.
    Vassilakopoulos, T. P.
    Sachanas, S.
    Panagoulias, G.
    Bartzis, V.
    Anargyrou, K.
    Dimou, M.
    Tzenou, T.
    Masouridis, S.
    Kalpadakis, C.
    Dimitrakopoulou, E.
    Kokoris, S. I.
    Dimitriadou, E.
    Siakantaris, M. P.
    Angelopoulou, M. K.
    Panayiotidis, P.
    Pangalis, G. A.
    [J]. HAEMATOLOGICA-THE HEMATOLOGY JOURNAL, 2008, 93 : 263 - 263
  • [22] Early M-Protein Dynamics Predicts Progression-Free Survival in Patients With Relapsed/Refractory Multiple Myeloma
    Yan, Xiaoyu
    Xu, Xu Steven
    Weisel, Katja C.
    Mateos, Maria-Victoria
    Sonneveld, Pieter
    Dimopoulos, Meletios A.
    Usmani, Saad Zafar
    Bahlis, Nizar J.
    Puchalski, Thomas
    Ukropec, Jon
    Bellew, Kevin
    Ming, Qi
    Sun, Steven
    Zhou, Honghui
    [J]. CTS-CLINICAL AND TRANSLATIONAL SCIENCE, 2020, 13 (06): : 1345 - 1354
  • [23] Soluble MICA as an independent prognostic factor for the overall survival and progression-free survival of multiple myeloma patients
    Rebmann, Vera
    Schuett, Philipp
    Brandhorst, Dieter
    Opalka, Bertram
    Moritz, Thomas
    Nowrousian, Mohammad Reza
    Grosse-Wilde, Hans
    [J]. CLINICAL IMMUNOLOGY, 2007, 123 (01) : 114 - 120
  • [24] Immunoglobulin Recovery after ASCT for Patients with Multiple Myeloma: Impact on Overall Survival and Progression-Free Survival
    Jimenez-Zepeda, Victor
    Duggan, Peter
    Neri, Paola
    Chaudhry, Ahsan
    Tay, Jason
    Bahlis, Nizar J.
    [J]. BLOOD, 2016, 128 (22)
  • [25] Progression-free survival as a surrogate for overall survival in advanced cancer.
    Gillies, Eric
    Holdai, Veera
    Cowall, David Eric
    [J]. JOURNAL OF CLINICAL ONCOLOGY, 2015, 33 (15)
  • [26] Progression-Free Survival as a Surrogate Marker of Overall Survival Is It the Good Question?
    Escudier, Bernard
    [J]. CANCER, 2011, 117 (12) : 2586 - 2587
  • [27] PROGRESSION-FREE SURVIVAL AS A SURROGATE FOR OVERALL SURVIVAL IN METASTATIC BREAST CANCER
    Beauchemin, C.
    Cooper, D.
    Lapierre, M. E.
    Yelle, L.
    Lachaine, J.
    [J]. VALUE IN HEALTH, 2012, 15 (07) : A414 - A414
  • [28] PROGRESSION-FREE SURVIVAL AS A SURROGATE FOR OVERALL SURVIVAL IN METASTATIC BREAST CANCER
    Beauchemin, C.
    Cooper, D.
    Lapierre, M.
    Yelle, L.
    Lachaine, J.
    [J]. ANNALS OF ONCOLOGY, 2012, 23 : 119 - 120
  • [29] Progression-Free Survival Early Assessment Is a Robust Surrogate Endpoint of Overall Survival in Immunotherapy Trials of Hepatocellular Carcinoma
    Cabibbo, Giuseppe
    Celsa, Ciro
    Enea, Marco
    Battaglia, Salvatore
    Rizzo, Giacomo Emanuele Maria
    Busacca, Anita
    Matranga, Domenica
    Attanasio, Massimo
    Reig, Maria
    Craxi, Antonio
    Camma, Calogero
    [J]. CANCERS, 2021, 13 (01) : 1 - 14
  • [30] APPLICATION OF PROGRESSION-FREE SURVIVAL AS SURROGATE ENDPOINT FOR OVERALL SURVIVAL IN NICE REVIEWS OF ADVANCED BREAST CANCER DRUGS
    Zou, D.
    Sun, A.
    Musci, R.
    Milev, S.
    [J]. VALUE IN HEALTH, 2022, 25 (01) : S183 - S184
12345